"Pneumocystis carinii" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prototype species of PNEUMOCYSTIS infecting the laboratory rat. It was formerly called Pneumocystis carinii f. sp. carinii. Strains that infect humans and cause PNEUMOCYSTIS PNEUMONIA were originally classified as Pneumocystis jirovecii or Pneumocystis carinii f. sp. hominis.
| Descriptor ID |
D045363
|
| MeSH Number(s) |
B01.300.107.730.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pneumocystis carinii".
Below are MeSH descriptors whose meaning is more specific than "Pneumocystis carinii".
This graph shows the total number of publications written about "Pneumocystis carinii" by people in this website by year, and whether "Pneumocystis carinii" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pneumocystis carinii" by people in Profiles.
-
Koon A, He J, Patel J, Morse A, Boseman V, Hamilton A, Knight T, Shah N, Ragon B, Chojecki A, Ai J, Steuerwald N, Gerber J, Copelan E, Grunwald M, Arnall J. Evaluation of pentamidine tolerability and efficacy between CYP2C19 phenotypes. Pharmacogenomics. 2023 Oct; 24(15):821-830.
-
Leidner F, Kurt Yilmaz N, Schiffer CA. Deciphering Antifungal Drug Resistance in Pneumocystis jirovecii DHFR with Molecular Dynamics and Machine Learning. J Chem Inf Model. 2021 06 28; 61(6):2537-2541.
-
Yoon C, Subramanian A, Chi A, Crothers K, Meshnick SR, Taylor SM, Beard CB, Jarlsberg LG, Lawrence GG, Avery M, Swartzman A, Fong S, Roth B, Huang L. Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort. Med Mycol. 2013 Aug; 51(6):568-75.
-
Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant. 2012 May-Jun; 26(3):E184-90.
-
Mu?oz C, Zuluaga A, Restrepo A, Tob?n A, Cano LE, Gonzalez A. Molecular diagnosis and detection of Pneumocystis jirovecii DHPS and DHFR genotypes in respiratory specimens from Colombian patients. Diagn Microbiol Infect Dis. 2012 Mar; 72(3):204-13.
-
Huang L, Welsh DA, Miller RF, Beard CB, Lawrence GG, Fox M, Swartzman A, Bensley MR, Carbonnet D, Davis JL, Chi A, Yoo BJ, Jones JL. Pneumocystis jirovecii dihydropteroate synthase gene mutations and human immunodeficiency virus-associated Pneumocystis pneumonia. J Eukaryot Microbiol. 2006; 53 Suppl 1:S114-6.